The actions of relaxin are mediated by relaxin family peptide receptor 1 (Rxfp1). In pregnant mice, myometrial Rxfp1 expression decreases at term, coinciding with the highest level of circulating relaxin. This down-regulation in Rxfp1 in reproductive tissues has not been investigated in other pregnant animals, nor are the regulatory mechanisms known. In the present study, we examined Rxfp1 gene and protein expression in the nonpregnant, pregnant, and postpartum rat uterus. The potential effects of local conceptus-derived factors on Rxfp1 expression were then examined in unilaterally pregnant rats. Immunoreactive RXFP1 was predominantly detected in the circular smooth muscle layer in the myometrium and in the decidualized endometrium. Rxfp1 was expressed in the rat myometrium from early to midgestation at levels similar to those in nonpregnant rat myometrium, with a significant reduction in expression at both the transcriptional and translational levels during late gestation. In unilaterally pregnant rats, myometrial Rxfp1 was higher in the nongravid compared to the gravid uterine horn, demonstrating a local negative influence of the fetal-placental unit on Rxfp1 expression. In summary, the downregulation in myometrial Rxfp1 expression at the end of gestation in the rat is partially mediated by the fetal-placental unit and is indicative of a functional withdrawal of relaxin. This may represent a novel mechanism for the activation of spontaneous uterine contractions at labor in this species. myometrium, parturition, pregnancy, relaxin, reproductive tract, RXFP1
INTRODUCTION
Throughout most of gestation, the myometrium remains in a noncontractile, quiescent state, but at term, it becomes capable of producing forceful contractions to deliver the fetus. This process involves the up-regulation and activation of several contractileassociated proteins (CAPs) in the myometrium and leads to increased uterine contractility [1, 2] . However, it also requires the withdrawal of mechanisms that maintain uterine quiescence, including inhibitors of CAPs. The ovarian peptide hormone relaxin is thought to act as an inhibitor of spontaneous myometrial contractions during pregnancy [3, 4] . In vitro studies show that porcine relaxin inhibits contractile activity in the nonpregnant (NP) and pregnant rat until midpregnancy, but that the myometrium is completely refractory to the inhibitory effect of relaxin by Gestational Day (GD) 19 [5, 6] . In NP ovariectomized rats and pigs, relaxin primarily reduces frequency rather than amplitude of spontaneous intrauterine pressure cycles (IUPCs) [7, 8] . Ovariectomized pregnant rats have a significantly greater frequency of IUPCs and reduced myometrial quiescence from mid to late gestation, an effect that is reversed by relaxin treatment [9] . Interestingly, the ability of relaxin to reduce the frequency of IUPCs in these rats is also diminished at term. However, it has not been established how the myometrium becomes refractory to relaxin in late pregnancy.
Evidence of relaxin receptors in the myometrium was initially provided by studies using radiolabeled ligand in autoradiography [10] [11] [12] or biotinylated porcine relaxin [13, 14] . In all species studied, high-affinity relaxin-binding sites were localized primarily to the inner circular layer of smooth muscle. The actions of relaxin are now known to be mediated through a leucine-rich repeat containing a heterotrimeric guanine nucleotide-binding, G-protein-coupled receptor known as Lgr7 [15] , subsequently referred to as relaxin family peptide receptor 1 (RXFP1) [16] . Rxfp1-specific b-galactosidase activity was identified in the circular layer of the myometrium of NP Rxfp1 mutant mice [17] . We have shown that Rxfp1 mRNA is predominantly expressed in the myometrium compared with the decidua or placenta of pregnant mice, with a down-regulation in myometrial Rxfp1 at term [18] . The one study in pregnant rats found Rxfp1 gene expression in the myometrium on GD 20 [19] , but no information is available regarding temporal expression throughout gestation, localization, or regulation of RXFP1 in the rat female reproductive tract.
Lye et al. [2] proposed that activation of myometrial contractility is mediated by the fetal-placental unit, partly through mechanical distension of the uterus and stretchmediated up-regulation of CAP expression in the myometrium. In particular, using the unilaterally pregnant rat model, they reported significantly higher oxytocin receptor (OTR), connexin-43, connexin-26, and fibronectin expression in the gravid uterine horn or artificially stretched horn compared with the nongravid horn, despite exposure to the same systemic endocrine environment [20] [21] [22] . Mechanical stretch also appears largely responsible for the up-regulation in OTR and prostaglandin H synthase 2 in the myometrium of the gravid horn in sheep around GD 130 and during labor [23] as well as in the gravid uterus of the tammar wallaby [24] . However, the effects of the fetal-placental unit on inhibitors of CAPs that maintain uterine quiescence have not been investigated. Therefore, the specific aims of the present study were, first, to localize RXFP1 protein and establish the temporal pattern of Rxfp1 gene and protein expression in the myometrium of the pregnant rat and, second, to determine whether the presence of the fetal-placental unit affects myometrial expression of Rxfp1 at term and during spontaneous labor.
MATERIALS AND METHODS

Animals
All animal experiments were conducted with ethical approval from each of the relevant institutional animal experimentation ethics committees. Two groups of Wistar rats were used for different aspects of the present study. The first group of rats was used in a pilot study (group A; Charles River Co.) and was housed at the Samuel Lunenfeld Research Institute under standard laboratory conditions with access to Purina Rat Chow (Ralston Purina) and water ad libitum. The day on which a vaginal plug was observed was designated as GD 1. Rats gave birth on the morning of GD 23. The second group of rats (group B; Animal Research Facility) was needed to increase the sample size and for protein analysis at specific stages of gestation based on the pilot study. These rats were housed under similar laboratory conditions at the Biological Research Facility (Departments of Pharmacology and Physiology, The University of Melbourne). The presence of sperm in the vaginal smear was taken as GD 1; rats gave birth on the morning of GD 22.
Experimental Design
Normal pregnancy and term labor. The aim of the present study was to establish the temporal pattern of Rxfp1 expression in the pregnant rat uterus. A pilot study was first conducted using the group A rats. Myometrial RNA was extracted from tissues obtained on GDs 6, 8, 10, 12, 14, 15, 17, 19, 21 , and 22; during labor on GD 23 (n ¼ 4 per day); and on Postpartum Days (PDs) 1 and 4 (n ¼ 4 per day) and was provided by Dr. Oksana Shynlova and Prof. Stephen Lye (Samuel Lunenfeld Research Institute). This enabled us to identify key stages of gestation for further analysis at both the transcriptional and the translational level, with a larger sample size per stage using group B rats. These rats were euthanized with ketamine overdose on GDs 8, 15, and 20 and on PD 1 (n ¼ 8 per day). Uterine horns were placed into ice-cold 0.1 M PBS, bisected longitudinally, and dissected away from pups and placentae. The decidualized endometrial tissue was carefully scraped away from the myometrium. Reproductive tract tissues were also obtained from nonpregnant (NP) rats (n ¼ 6). To localize RXFP1 protein in the rat uterus, uterine segments from a virgin NP rat and a pregnant rat on GDs 8, 15, and 20 were fixed in PLP fixative (8% paraformaldehyde, 0.2 M lysine, 0.01 M PBS in 0.1 M) for 24 h and then transferred to 0.1 M PBS. Midsegments of the cervix and vagina were also fixed as a positive-control tissue in immunohistochemistry.
Unilaterally pregnant rats. The present study used RNA kindly provided by Dr. Oksana Shynlova and Prof. Stephen Lye. Under general anesthesia, mature virgin female rats underwent unilateral tubal ligation through a flank incision to ensure they subsequently became pregnant in only one uterine horn [21] . Animals were allowed to recover from surgery for at least 7 days before they were mated to obtain timed pregnancies. Pregnant rat myometrial samples from nongravid (empty) and gravid horns were collected as described on GDs 12, 14, 15, 17, 19, 21, 22 , and 23 (labor) and on PD 1 (n ¼ 4 per day).
RNA Extraction
Total RNA was extracted from frozen tissues using either the Micro-toMidi Total RNA Purification System kit (Invitrogen) or Trizol (Gibco BRL) according to the manufacturer's instructions. The RNA was then treated with 2 U of DNase I to remove genomic DNA contamination. The concentration of RNA was determined using a Bio-Rad Smart Spec 3000, with A 260 :A 280 absorbance ratios of greater than 1.9 indicating sufficiently pure RNA for PCR analysis. First-strand cDNA synthesis used 1 lg of total RNA in a 20-ll reaction, with random hexamers (50 ng/ll) and 200 U of SuperScript III (Invitrogen). The reaction was terminated by increasing the temperature to 858C for 5 min. Next, 1 U of RNase H was added to each sample, and samples were incubated at 378C for 20 min to remove any excess RNA.
Quantitative PCR
Relative quantification of Rxfp1 gene expression used the comparative cycle threshold (DDC T ) method with ribosomal 18S as the reference gene. Forward/reverse primers and 6-carboxy fluorescein-labeled TaqMan probes specific for the full-length rat Rxfp1 were designed and purchased from Biosearch Technologies. Primers were designed to span intron/exon boundaries and avoid Rxfp1-truncates [19, 25] . They also shared no homology with the other known relaxin-like receptors. Quantitative PCR (qPCR) was performed in the DNA Engine Opticon2 monitor (MJ Research, GeneWorks) or on the Rotor-Gene v6 (Corbett Research) in 20-ll volumes in triplicate containing Platinum Supermix uracil DNA glycosylase (Invitrogen). To establish amplification efficiencies, a cDNA sample of each tissue type was serially diluted 1:4, 1:8, 1:16, 1:32, and 1:64, and 2 ll of each were used in a PCR reaction. The slope of the log-linear portion of the calibration curve comparing log input amount of cDNA and DC T was equivalent and less than 0.1 for both Rxfp1 and Rn18s. The optimal cDNA concentration was chosen based on the cycle threshold value, which increased by one unit between each dilution. We established that a 1:16 cDNA dilution produced optimum and equivalent efficiencies for Rxfp1 and Rn18s. In addition, myometrial Rn18s expression did not differ significantly (P . 0.05) across gestation or in response to unilateral pregnancy. All PCR reactions for both genes were performed at the same time, and the mean Rn18s C T value of each triplicate was subtracted from the corresponding mean Rxfp1 C T triplicate value to normalize gene-of-interest expression to the reference gene. These normalized data were then presented as a value relative to NP rats and plotted with the SD (see ABI User's Bulletin 2, http://www3.appliedbiosystems.com/cms/groups/mcb_support/documents/ generaldocuments/cms_040980.pdf). Gene expression for tubal-ligated rats was relative to GD 12 gravid uterine horn. To demonstrate the amplification of a single PCR product, 20 ll of representative PCR products were run on 3% agarose gels at 100 V for 30 min.
Immunohistochemistry
Tissue samples were dehydrated in a graded series of ethanols and embedded in polyester wax (polyethylene glycol 400 distearate; Polysciences), after which sections (thickness, 3 lm) were cut and mounted on gelatin-coated glass slides. A rabbit anti-rat RXFP1 antisera (no. 107, raised against amino acid residues 107-119 of the rat RXFP1 protein) was kindly supplied by Prof. O.D. Sherwood (Department of Physiology & Biophysics, University of Illinois, Urbana) and purified on protein A agarose affinity columns (Antibodies Australia). Appropriate dilutions for immunostaining were determined in pilot studies. After quenching endogenous peroxidase with 0.3% hydrogen peroxide, sections were incubated in 2% normal goat serum for 1 h. The primary antiserum and preimmune serum (rabbit immunoglobulin [Ig] G) negative controls were diluted to a concentration of 1 lg/ml. An additional negative control was primary antiserum (3 lg/ml) preabsorbed overnight with 3 lg/ml of rat relaxin. The sections were incubated with either RXFP1 antiserum 107, preimmune serum, or RXFP1 antiserum 107 with rat relaxin overnight at 48C. MACH 2 polymer horseradish peroxidase (HRP) conjugate (Biocare Medical) with diaminobenzidine as the chromagen substrate (Vector Laboratories) was used according to the manufacturer's instructions to detect immunoreactive RXFP1. Sections were counterstained with hematoxylin. The experiment was run three times on different sections. Representative sections were photographed using the Nikon Coolscope during the same session, using the same camera and microscope settings, and any adjustments were done to the montage as a whole, not to individual micrographs. Comparisons were made between sections of the same thickness and immunohistochemistry experiment to eliminate minor differences in intensity from run-to-run variability.
Western Blot Analysis
Myometrial samples from the NP rats as well as from rats at GDs 8, 15, and 20 (n ¼ 6 per day) were used in this method of analysis. Approximately 100 mg of tissue were homogenized in a Digital Wig-L-Bug amalgamator (Dentsply Ltd.) and resuspended in 1 ml of extraction buffer (pH 7.5), which consisted of 50 mM Tris, 1 mM ethylenediaminetetra-acetic acid, 10% glycerol, 1% Triton X-100, 10% sodium fluoride, 10% sodium pyrophosphate, 0.1% trypsin inhibitor, 0.1% dithiothreitol, 10 ll/ml of phenylmethyl sulfonyl fluoride, and 5 ll/ml of Calbiochem Protease Inhibitor Cocktail Set III (Calbiochem). Protein extracts (50 lg) were combined with one-third volume of 33 Laemelli sample buffer (6% SDS, 30% glycerol, and 0.06% bromophenol blue in 0.185 M TrisHCl, pH 6.8) containing 7.5% b-mercaptoethanol. Samples were denatured by boiling for 5 min before loading into 30-ll Pre-Cast 7.5% Tris-glycine/SDS gels (Bio-Rad Australia). Five microliters (1:4 dilution) of Precision Plus Protein Western C Standards (Bio-Rad Australia) were included on the blot so that protein size could be determined. The separated proteins were transferred onto polyvinylidene difluoride membranes (Bio-Rad Australia) for 90 min at 95 V. After transfer, membranes were soaked briefly in methanol and then rehydrated in Tris-buffered saline (TBS; 10 mM Tris and 150 mM NaCl, pH 7.4) containing 0.05% Tween 20 (TTBS) before blocking for 1 h in 5% nonfat dried milk (NFDM; Bio-Rad Australia) diluted in TTBS. Immunoblots were
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DAKO) diluted in the same manner as the primary antibody. After washes in TTBS, blots were incubated for 1 h at room temperature with HRP-conjugated goat anti-rabbit secondary antibody (BioRad Australia) diluted 1:50 000 in NFDM. The blots were again washed in TTBS, followed by a final rinse in TBS. The chemiluminescent substrate reagent ECL (Amersham, GE Healthcare Bio-Sciences Pty Ltd.) was applied to the blots for 5 min and the membrane viewed in the ChemiDoc XR Gel Documentation System (Bio-Rad Australia) for signal detection. All membranes were subsequently reprobed with HRPconjugated tubulin (1:20 000; Abcam) as a loading control. We also ran two further samples as positive controls: late gestation rat cervix (GD 20) and late gestation mouse cervix (GD 16.5). Both samples were treated in the same way as described for the myometrium, except the mouse cervix membrane was incubated with a monoclonal anti-human RXFP1 antibody (1 lg/ml; Abnova, Sapphire Bioscience Pty Ltd.) characterized in previous studies [26, 27] . Data were quantified using densitometry software (Quantity One; Bio-Rad Australia), with appropriate corrections for background.
Statistical Analysis
One-way ANOVA and post hoc Tukey tests were conducted with SPSS software (SPSS, Inc.) to examine for significant differences in myometrial (A and B) , vagina (C), and cervix (I) on GD 15 and in the uterus from an NP rat (G and H). Sections (A-C, G, and H) were incubated with antiserum 107 (1 lg/ml), specific to rat RXFP1, whereas the controls used preimmune rabbit serum (1 lg/ml; D) or RXFP1 antiserum preabsorbed with rat relaxin overnight (E and F). Note the intense RXFP1 immunostaining (arrow) in the circular myometrium (CM) and decidua (D) compared with the longitudinal myometrium (LM) in the pregnant rat. In the vagina and cervix (positive control), intense RXFP1 immunostaining (arrow) is seen under the basal layer of the epithelium. D, decidua; EG, endometrial gland; Endo, endometrium; GT, trophoblast giant cells; L, lumen; S, stroma. Bars ¼ 500 lm (A-G and I) and 200 lm (H). The box in A is enlarged in B, and the box in G is enlarged in H.
VODSTRCIL ET AL.
Rxfp1 gene and protein expression between stages of gestation and for Rxfp1 expression between different reproductive tissues in the Melbourne samples. The alpha criterion level (type I error) was set at 0.05. Because of the smaller sample size for the expanded gestational stage study, we used a Dunnett t-test post hoc relative to the NP state. The effects of unilateral pregnancy on Rxfp1 expression at different stages of gestation in the rat were analyzed by paired ttests to determine significant differences between gravid and nongravid uterine horns.
RESULTS
A comparison of relative Rxfp1 gene expression between reproductive tract tissues was conducted on rats at GD 20 ( Fig.  1) . Rxfp1 gene expression was highest (P , 0.01) in the cervix and vagina, with relatively equal expression in the myometrium and decidualized endometrium (cervix . vagina . myometrium ¼ endometrium).
Immunoreactive RXFP1 was identified in all tissues expressing Rxfp1 mRNA. On GD 15, RXFP1 protein was predominantly localized in the circular smooth muscle layer of the myometrium (Fig. 2, A and B) , with weaker staining in the longitudinal muscle layer. This differed from the NP virgin rat, which had equal immunoreactive RXFP1 in the circular and longitudinal muscles (Fig. 2G) . No RXFP1 immunostaining was seen in the negative controls, in which the primary antiserum was replaced either with RXFP1 antiserum preabsorbed with rat relaxin (Fig. 2D ) or preimmune serum (Fig.  2E) , demonstrating specificity of the antiserum for RXFP1. Strong RXFP1 immunostaining was seen in the decidualized endometrium of the GD 15 rat, predominantly in the stroma (Fig. 2, A and B) . Immunoreactive RXFP1 was detected in the endometrial stroma and epithelium in the NP rat (Fig. 2H) but at reduced intensity compared with that in the pregnant rat. Figure 2 also shows the intense RXFP1 immunostaining under the basal layer of the vaginal epithelium and throughout the stroma on GD 15 (Fig. 2C) . Immunoreactive RXFP1 was not detected in the negative control (Fig. 2F ) or in the vaginal epithelium (Fig. 2C) . Similar to the vagina, immunoreactive RXFP1 was also localized to the stroma in the cervix, with the highest intensity of immunostaining under the basal layer of epithelium, but not in the epithelium itself (Fig. 2I) .
The temporal pattern of Rxfp1 mRNA expression in the myometrium of pregnant rats was the same in both group A and group B rats despite minor differences in gestation lengths (Figs. 3 and 4) . A significant (P , 0.05) decrease in Rxfp1 was found at the end of gestation, whereas immediately postpartum, Rxfp1 expression increased to NP levels. In both groups, we used primers and probes specific to the full-length Rxfp1 and found only one amplicon in the PCR reaction at the end of the 40-cycle program (data not shown). The detailed analysis of myometrial Rxfp1 expression throughout the full gestational profile in group A rats demonstrated no significant (P . 0.05) change in Rxfp1 between GD 8 and 19 compared to NP levels (Fig. 3) . However, starting from GD 21, myometrial Rxfp1 expression was significantly (F 13,51 ¼ 4.468, P , 0.01) lower relative to NP. Rxfp1 remained low throughout the peripartum period and during spontaneous term labor, and increased postpartum. In the group with the larger sample size (group B rats), no difference was found in Rxfp1 expression between the NP state and GD 8 (Fig. 4) . However, the decrease in Rxfp1 expression was significant (F 4,35 ¼ 20.93, P , 0.01) on GD 15 as well as on GD 20 compared with the NP state. A postpartum increase was also observed in myometrial Rxfp1 expression.
Under reducing conditions, Western blot analysis demonstrated a predominant immunoreactive protein of approximately 75 kDa and a faint band at approximately 60 kDa in rat myometrium at all stages of gestation examined (Fig. 5, A and  B) . These protein bands were substantially reduced when rabbit IgG was substituted for the primary antibody. The presence of an approximately 75-kDa protein was verified in the two positive-control tissues, rat and mouse cervix, using different antibodies. In addition, a protein of higher molecular weight (;120-125 kDa) was found in the two cervix samples (Fig.  5A) . A significant (F 3,20 ¼ 31.35, P , 0.01) decrease in the approximately 75-kDa RXFP1 protein was observed on GDs 8, 15, and 20 compared with NP, as was a significant decrease between GD 8 and GDs 15 and 20 (Fig. 5, B and C) . Immunoreactive RXFP1 was also decreased in the two layers of the myometrium on GD 20 compared with GD 8 (Fig. 5D) . On GD 8, immunoreactive RXFP1 was detected in both circular and longitudinal smooth muscle, but it was substantially reduced in the latter muscle layer on GD 20.
We utilized an in vivo unilateral pregnant rat model to show if the presence of the conceptus affects myometrial Rxfp1 expression. The profile of myometrial Rxfp1 gene expression in the gravid uterine horn of unilateral pregnant rats was similar to that in normal pregnant rats (Fig. 6) . On GD 12, the expression of Rxfp1 was equal between gravid and empty uterine horns. However, starting from GD 14, Rxfp1 was significantly (P , REGULATION OF MYOMETRIAL Rxfp1 EXPRESSION 821 0.05) higher in the nongravid uterine horn compared to the gravid horn, indicating the effect of uterine occupancy during late gestation. During the postpartum period, expression of Rxfp1 increased in both uterine horns.
DISCUSSION
To our knowledge, this is the first study to document the profile of Rxfp1 gene and protein expression in the myometrium of pregnant rats. Specifically, we identified a decrease in RXFP1 receptors in late pregnancy compared to the NP state and early gestation. Our finding of a major RXFP1 protein of approximately 75 kDa in the rat myometrium and cervix using the rat RXFP1 antiserum, and in the mouse cervix using a different RXFP1 antiserum (anti-human RXFP1), differs from an earlier report of RXFP1 proteins of 87-100 kDa in the rat atrium and mouse myometrium [28] . It should be noted that a protein band of approximately 75 kDa was detected in the mouse and rat atrium, but not myometrium, in the study by Novak et al. [28] . A higher-molecular-weight immunoreactive RXFP1 protein of between 120 and 125 kDa was also detected in cervix tissues of both species. The approximately 75-kDa protein is of similar molecular weight to the immunoreactive proteins detected in isolated primary decidual cells with the same human RXFP1 antiserum used in our study [27] . In contrast, higher-molecular-weight proteins (95 and 80 kDa) were detected in HEK293 cells transfected with hemagglutinintagged RXFP1 [27] . Because RXFP1 is highly glycosylated in HEK293 cells [26] , authors concluded that differences in the glycosylation of RXFP1 within primary decidual cells versus HEK293 cells might result in RXFP1 proteins of different molecular weight. Kern et al. [26] proposed that the 95-kDa RXFP1 protein expressed in HEK-RXFP1 cells likely is the mature form delivered to the cell surface, whereas the 80-kDa protein is an immature form accumulated in the endoplasmic reticulum. The consistent finding in rat myometrium and cervix, mouse cervix, and isolated human decidual cells is the presence of an approximately 75-to 80-kDa RXFP1 protein.
Our interpretation is that this protein represents a mature form of the RXFP1 receptor, whereas the smaller, 60-kDa protein could either be a precursor receptor or a deglycosylated form of the receptor and the 120-to 125-kDa proteins could be glycosylated forms.
A decrease in Rxfp1 gene expression has been demonstrated in both the myometrium [29] and cervix [30] of the pregnant mouse. We detected that myometrial Rxfp1 gene and protein expression did not increase between the NP state and midgestation. This might have been expected given the putative role for relaxin as an inhibitor of spontaneous uterine contractions throughout most of pregnancy. Our data support the concept that relaxin acts directly on the myometrium and is likely to reduce smooth muscle contractions by inhibiting the activation of CAPs. The down-regulation of relaxin receptors in the myometrium may explain why relaxin is less effective as an inhibitor of spontaneous uterine contractions or IUPCs at term and may function as a mechanism of relaxin withdrawal to enable activation of CAPs and spontaneous labor at term.
Several in vitro and in vivo studies show relaxin treatment decreases IUPCs, spontaneous myometrial activity, or oxytocin-induced uterine contractions [5] [6] [7] [8] [9] . Various mechanisms of relaxin action have been proposed to account for the uterine quiescence. Relaxin increases calcium efflux from smooth muscle cells [31] , decreases myosin light-chain kinase phosphorylation [32] , stimulates calcium-activated potassium channels via a protein kinase A-mediated mechanism [33, 34] , and has been shown to induce phosphorylation of phospholipase Cb3 [35] . In addition, relaxin decreases oxytocinstimulated myometrial contractions by inhibiting phosphatidyl-inositol phosphate turnover and suppressing phospholipase C [36] . Work in primary human myometrial cells suggests that relaxin inhibition of myometrial contractile activity involves activation of adenylate cyclase and generation of cAMP, which is dependent on tyrosine phosphorylation [37] . These effects of relaxin on cAMP production are specifically mediated through RXFP1, expressed in these primary human myometrial cells [37] .
Our immunohistochemistry data show that RXFP1 is predominantly localized to rat myometrial cells in the circular smooth muscle layer. In the NP state and early pregnancy, however, equivalent RXFP1 immunostaining is found in the rat longitudinal muscle layer. By the end of gestation, we observed a large reduction in RXFP1, particularly in the longitudinal muscle. This may explain the wide range of effects and mechanisms of relaxin action on the two layers of uterine smooth muscle [38] . In the longitudinal layer, the relaxin inhibition is transient, and tachyphylaxis develops. In contrast, relaxin treatment abolishes the plateau component of the action potential, characteristic of the electrical activity of the circular myometrium, thus reducing the contractile response by 10%. Our localization data support these functional studies and confirm that the main inhibitory target of relaxin action at the end of gestation is the circular layer of the myometrium.
Because the decrease in Rxfp1 gene expression occurred during late gestation, when mechanical stretch of uterine walls imposed by growing fetuses is maximal, we used a wellcharacterized model of unilateral pregnancy to study the effect of mechanical distention. Myometrial Rxfp1 expression in the gravid horn was markedly reduced throughout mid and late gestation compared with the nongravid horn. Therefore, we concluded that uterine occupancy is mostly responsible for the decline in myometrial Rxfp1 at term and during labor. Importantly, immediately after delivery, during the period of postpartum involution, the expression of Rxfp1 increases. Previous work has identified the importance of mechanical stretch in activating several CAPs and factors involved in the coordination of smooth muscle contractions and onset of labor [2, [20] [21] [22] . In early pregnancy [22] , the uterus grows noticeably in a longitudinal direction, followed by circumferential growth from midpregnancy onward. It would thus be expected that tension on the uterine wall during late pregnancy is predominant in the circular smooth muscle layer. Indeed, in the present study, RXFP1 protein distribution demonstrated differential expression between the circular myometrial layer and the longitudinal layer. The circular layer of the myometrium is more responsive to mechanical stretch than the longitudinal layer [22, 39, 40] in late gestation. We propose now that the timely, coordinated, stretch-induced inhibition of RXFP1 serves as an additional mechanism supporting the increase in myometrial contractility at term, especially in the circular myometrial layer. To our knowledge, our data are the first to show that the presence of the fetal-placental unit mediates the repression of mechanisms that maintain uterine quiescence throughout gestation.
The decrease in Rxfp1 at term, however, also coincides with the decline in circulating progesterone and with the highest plasma concentrations of relaxin itself during late gestation [41] . We have previously hypothesized that relaxin is capable of regulating Rxfp1. Chronic infusion of relaxin in pregnant relaxin mutant mice (Rln À/À ) decreases Rxfp1 gene expression in the myometrium [29] and cervix [30] compared to salinetreated Rln À/À controls. Relaxin treatment in the neonatal pig also reduces cervical, but not myometrial, Rxfp1 expression [42] . Ovariectomized, estrogen-treated rats treated with relaxin have reduced relaxin-binding capacity in the myometrium, demonstrating fewer relaxin receptors [43] . Therefore, we suggest that increased circulating levels of relaxin in late gestation could mediate the down-regulation of myometrial Rxfp1. We cannot rule out the possibility that progesterone withdrawal also contributes to the down-regulation of Rxfp1 in late pregnancy, although Rxfp1 expression was reduced on GD 15 before the decline in plasma progesterone. Progestin treatment of human stromal cells in vitro increases Rxfp1, so a functional withdrawal of progesterone in late gestation could cause a reduction in Rxfp1 expression in the myometrium. However, the role of progesterone as a regulator of Rxfp1 is yet to be elucidated in vivo.
In summary, we determined the expression profile of the relaxin receptor, Rxfp1, in the myometrium of NP, pregnant, and postpartum rats. We propose that the down-regulation in myometrial Rxfp1 at the end of gestation may represent a functional withdrawal of relaxin and is partially mediated by the presence of the fetal-placental unit. This may be necessary for the peripartum activation of CAPs and onset of spontaneous labor in the rat.
REGULATION OF MYOMETRIAL
Rxfp1 EXPRESSION
